Afimetoran

DRUG4 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Beeline Medicines Corporation, Bristol-Myers Squibb

Conditions

Active Systemic Lupus ErythematosusHealthy ParticipantsHealthy VolunteersSystemic Lupus Erythematosus

Phase 1

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

CompletedNCT05866627

Bristol-Myers SquibbHealthy Volunteers

Start: 2023-07-04End: 2023-09-29Updated: 2026-05-13

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

CompletedNCT05901714

Bristol-Myers SquibbHealthy Participants

Start: 2023-06-14End: 2024-04-11Updated: 2024-08-07

Phase 2

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Active, not recruitingNCT04895696

Beeline Medicines CorporationSystemic Lupus Erythematosus

Start: 2021-10-11End: 2029-04-22Updated: 2026-08-17

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants with Active Systemic Lupus Erythematosus.

Active, not recruitingCTIS2023-504320-25-00

Bristol-Myers Squibb Services Unlimited CompanyActive Systemic Lupus Erythematosus

Start: 2021-11-25Target: 86Updated: 2025-12-10

Related Papers

PO.1.1 Afimetoran, a potent and selective inhibitor of human toll-like receptor 7 (TLR7) and tlr8, provides robust efficacy in a murine lupus model of advanced disease

2022-09-273 citations

PO.6.132 A phase 2b study of afimetoran (BMS-986256) in patients with active systemic lupus erythematosus (SLE): optimization of a lupus clinical trial design

2022-09-272 citations